Feasibility of a cannabidiol‐dominant cannabis‐based medicinal product for the treatment of long COVID symptoms: A single‐arm open‐label feasibility trial

Abstract

AimsTo conduct a single arm open‐label feasibility trial of the safety and tolerability of a full‐spectrum cannabidiol (CBD)‐dominant cannabis‐based medicinal product (CBMP) for treating the symptoms of Long COVID.MethodsThe treatment phase ran for a total of 21 weeks, followed by ~3 weeks without the study drug. Participants received up to 3 mL of MediCabilis 5% CBD Oil (50 mg CBD/mL, <2 mg delta‐9‐tetrahydrocannabinol (THC)/mL) per day orally. Monthly patient reported outcome measures (PROMs) of common symptoms and daily self‐report of symptoms were collected via a smartphone app. Key measures of heart rate, activity, sleep, and oxygen saturation were assessed using wearable technology.Results12 (1 male, 11 female) individuals diagnosed with Long COVID were recruited into the trial. All patients adhered to the treatment protocol for the duration of the study and there were no serious adverse events. Response rates for the research assessments were high with over 90% completion of PROMs and daily self‐report.ConclusionThe study drug was safe and well tolerated, demonstrating feasibility of CBD‐dominant CBMPs in individuals diagnosed with Long COVID. However, there were limitations in research design related to recruitment strategy demonstrating a lack of feasibility in the approach implemented in this study. Future work with larger samples and incorporating a control group are required to test the efficacy of this treatment.